A median PFS of 14.9 months for the combination therapy compared to 7.3 months for vemurafenib (HR 0.54; 95% CI 0.41–0.71; P < 0.001) was reported in patients with BRAF mutant melanoma, with a favorable safety profile for the combination [51]. This evidence concerns the gene BRAF and melanoma.